[go: up one dir, main page]

NO20005884D0 - Kombinasjonsterapi for behandling av bipolare forstyrrelser - Google Patents

Kombinasjonsterapi for behandling av bipolare forstyrrelser

Info

Publication number
NO20005884D0
NO20005884D0 NO20005884A NO20005884A NO20005884D0 NO 20005884 D0 NO20005884 D0 NO 20005884D0 NO 20005884 A NO20005884 A NO 20005884A NO 20005884 A NO20005884 A NO 20005884A NO 20005884 D0 NO20005884 D0 NO 20005884D0
Authority
NO
Norway
Prior art keywords
treatment
combination therapy
bipolar disorders
bipolar
disorders
Prior art date
Application number
NO20005884A
Other languages
English (en)
Other versions
NO20005884L (no
Inventor
Gary Dennis Tollefson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20005884D0 publication Critical patent/NO20005884D0/no
Publication of NO20005884L publication Critical patent/NO20005884L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
NO20005884A 1998-05-29 2000-11-21 Kombinasjonsterapi for behandling av bipolare forstyrrelser NO20005884L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8712698P 1998-05-29 1998-05-29
PCT/US1999/011314 WO1999062522A1 (en) 1998-05-29 1999-05-21 Combination therapy for treatment of bipolar disorders

Publications (2)

Publication Number Publication Date
NO20005884D0 true NO20005884D0 (no) 2000-11-21
NO20005884L NO20005884L (no) 2001-01-24

Family

ID=22203275

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005884A NO20005884L (no) 1998-05-29 2000-11-21 Kombinasjonsterapi for behandling av bipolare forstyrrelser

Country Status (19)

Country Link
EP (1) EP0966967A3 (no)
JP (1) JP2002516864A (no)
KR (1) KR20010043731A (no)
CN (1) CN1302207A (no)
AU (1) AU756468B2 (no)
BR (1) BR9911068A (no)
CA (1) CA2332408A1 (no)
CZ (1) CZ20004280A3 (no)
EA (1) EA003611B1 (no)
HR (1) HRP20000798A2 (no)
HU (1) HUP0102511A2 (no)
IL (1) IL139591A0 (no)
NO (1) NO20005884L (no)
NZ (1) NZ507981A (no)
PL (1) PL344304A1 (no)
SK (1) SK17492000A3 (no)
TR (1) TR200003525T2 (no)
WO (1) WO1999062522A1 (no)
ZA (1) ZA200006817B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
EP1133299A1 (en) * 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
FR2802101B1 (fr) * 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6627653B2 (en) 2000-08-02 2003-09-30 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
MXPA03006003A (es) * 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.
JP2004527553A (ja) * 2001-04-26 2004-09-09 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 抗痙攣性誘導体と非典型的抗精神病薬を用いた共治療を含んで成る精神病性障害治療
MXPA05000294A (es) 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
WO2004047727A2 (en) 2002-11-01 2004-06-10 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosing and treating mood disorders
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
EP1723957A3 (en) 2002-12-27 2013-01-23 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
AU2004237961A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Treatment of bipolar disorders and associated symptoms
UA92453C2 (ru) * 2003-05-23 2010-11-10 Оцука Фармасьютикел Ко., Лтд. Производные карбостирила и стабилизаторы настроения для лечения расстройств настроения
EP1713486A4 (en) * 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
WO2005056056A2 (en) * 2003-12-15 2005-06-23 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
US20070264358A1 (en) * 2004-06-04 2007-11-15 Wittlin William A Methods and Compositions for Treating Mood Disorder
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EP1766077B1 (en) 2004-06-21 2012-03-28 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
AU2006315562C1 (en) 2005-11-12 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating depression using NCAM peptide mimetics
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
AU2007253814A1 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
US20080199866A1 (en) * 2006-10-10 2008-08-21 The Board Of Trustees Of The Leland Stanford Junior University Snp detection and other methods for characterizing and treating bipolar disorder and other ailments
GB0814466D0 (en) * 2008-08-07 2008-09-10 Rosemont Pharmaceuticals Ltd Sertraline composition
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN108938645A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种抗精神病药物组合物
CN108926569A (zh) * 2018-08-24 2018-12-04 山西医科大学第医院 一种非典型抗精神病药物组合物
CN109464436A (zh) * 2019-01-10 2019-03-15 高智玉 西酞普兰或艾司西酞普兰分别和喹硫平联合在制备治疗精神障碍类疾病的复方制剂中的应用
CN110151718A (zh) * 2019-06-13 2019-08-23 厦门医学院 一种奥氮平口腔崩解片及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000103A1 (en) * 1990-06-28 1992-01-09 Beecham Group Plc Pharmaceutical preparations
CZ290298A3 (cs) * 1996-03-11 1999-10-13 Eli Lilly And Company Farmaceutický prostředek proti bipolárních poruše
PL187926B1 (pl) * 1996-03-25 2004-11-30 Lilly Co Eli Kompozycja farmaceutyczna do leczenia bólu
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Also Published As

Publication number Publication date
AU4008899A (en) 1999-12-20
SK17492000A3 (sk) 2002-04-04
EP0966967A2 (en) 1999-12-29
IL139591A0 (en) 2002-02-10
CZ20004280A3 (cs) 2001-09-12
EP0966967A3 (en) 2000-05-31
AU756468B2 (en) 2003-01-16
EA003611B1 (ru) 2003-06-26
NZ507981A (en) 2003-10-31
ZA200006817B (en) 2002-02-21
KR20010043731A (ko) 2001-05-25
CA2332408A1 (en) 1999-12-09
WO1999062522A1 (en) 1999-12-09
CN1302207A (zh) 2001-07-04
EA200001244A1 (ru) 2001-06-25
JP2002516864A (ja) 2002-06-11
NO20005884L (no) 2001-01-24
TR200003525T2 (tr) 2001-04-20
HRP20000798A2 (en) 2001-10-31
PL344304A1 (en) 2001-10-22
BR9911068A (pt) 2001-02-06
HUP0102511A2 (hu) 2001-11-28

Similar Documents

Publication Publication Date Title
NO20005884L (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
NO20005864D0 (no) Quinasoler til behandling av hjernesvulst
NO991381L (no) Kombinasjonsterapi for behandling av psykoser
NO993051L (no) Intranasale formuleringer for behandling av seksuelle forstyrrelser
NO20010882L (no) Terapier for behandling av lungesykdommer
NO951761D0 (no) Stabilt preparat for behandling av blodkoagulasjonssykdommer
NO20005885L (no) Kombinasjonsterapi for behandling av refraktær depresjon
NO990722D0 (no) FremgangsmÕte for behandling av hjertesvikt
HUP0201791A3 (en) The use of escitalopram for treatment of neurotic disorders
NO20010456L (no) Triazolopyridiner for behandling av trombose lidelser
ID23528A (id) Pengobatan terapeutik untuk gangguan kulit
NO20012106L (no) Middel for behandling av forstyrrelser i benmetabolismen
NO984432L (no) FremgangsmÕte for behandling av migrenesmerte
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
NO20011892L (no) 3-tetrahydropyridin-4-yl-indoler for behandling av psykotiske forstyrrelser
NO20010390D0 (no) Behandling av angstsykdommer
NO984189D0 (no) Fremgangsmåte for behandling av bipolar forstyrrelse
NO20012612D0 (no) Isonipecotamider for behandling av integren-formidlede lidelser
NO20003481D0 (no) FremgangsmÕte for behandling av COPD
NO20002481D0 (no) Kombinasjonsterapi for behandling av AIDS
PT1200447E (pt) Oxazinocarbazoles para o tratamento de doencas do snc
NO952411D0 (no) Midler for behandling av metaboliske bensykdommer
IS6020A (is) S-nítrósóþíól til meðferðar við blóðrásartruflunum
ATE204167T1 (de) Antikonvulsive derivate zur behandlung von psoriasis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application